The Peroxisome Proliferator Activated Receptor Delta pipeline drugs market research report outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Delta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Peroxisome Proliferator Activated Receptor Delta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Metabolic Disorders, Central Nervous System, and Oncology which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Type 2 Diabetes, Diabetes, Alzheimer’s Disease, Parkinson’s Disease, Oncology, and Unspecified Cancer. It also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta targeted therapeutics development with respective active and dormant or discontinued products.
The Peroxisome Proliferator Activated Receptor Delta pipeline targets constitutes close to 18 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 3, 1, 1, 2, 1, and 7 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Peroxisome Proliferator Activated Receptor Delta overview
Peroxisome proliferator-activated receptor delta is a nuclear receptor that in humans is encoded by the PPARD gene. PPAR-delta is a nuclear hormone receptor that governs a variety of biological processes and involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer. The expression of this gene is found to be elevated in colorectal cancer cells. The elevated expression can be repressed by adenomatosis polyposis coli (APC), a tumor suppressor protein involved in the APC/beta-catenin signaling pathway.
For a complete picture of Peroxisome Proliferator Activated Receptor Delta’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
